Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC05F01 in relapsed/refractory ovarian cancer and other advanced solid tumors
CTR20233918Phase 2Active
- Sponsor
- Beijing Shuanghe Runchuang Technology
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of DC05F01 in ovarian cancer, Nonhematologic neoplasms, sponsored by Beijing Shuanghe Runchuang Technology. Started Sep 2024; status: active.
02
Drugs
DC05F01
03
Conditions
ovarian cancerNonhematologic neoplasms
Beyond the preview
Go deeper on CTR20233918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233918.